halo thanks

Article

Your one click will help provide emergency medical care to millions of people caught in crises in nearly 60 countries around the world.

Thank you for joining the movement.

Your one click will help provide emergency medical care to millions of people caught in crises in nearly 60 countries around the world.

Now, help spread the word!

Just one more click helps us spread the movement far and wide. Be sure to share this link with your friends and colleagues in the healthcare profession.

 

Thank you for spreading the word!

 

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.

Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML

Bridget Hoyt
December 6th 2025
Article

Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Zanubrutinib Plus R-CHOP Elicits High ORR in Untreated DLBCL With BRCR Expression

Zanubrutinib Plus R-CHOP Elicits High ORR in Untreated DLBCL With BRCR Expression

Kyle Doherty
December 6th 2025
Article

An ORR of 91.4% was observed with zanuburtinib plus R-CHOP in patients with DLBCL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Catastrophic Income Loss Observed Among Families of Children with ALL

Alex Biese
December 6th 2025
Article

A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Tim Cortese
December 6th 2025
Article

Elevated LDH levels were associated with worse PFS and OS outcomes in patients with relapsed/refractory multiple myeloma treated with elranatamab.